Avastin non-inferior to Eylea in Phase III CRVO trial

NIH’s National Eye Institute (NEI) reported that intravitreal Avastin bevacizumab was non-inferior to Eylea aflibercept on the primary endpoint of mean change in visual acuity in the Phase III SCORE2 trial to treat central retinal vein occlusion. Data were published in the Journal of the American Medical Association.

At six months, Avastin improved mean visual acuity from baseline by 18.6 letters compared to 18.9 letters for Eylea (p=0.001 for non-inferiority). The non-inferiority margin was five letters...